Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Importer's Entry Notice, 14255-14256 [2014-05516]

Download as PDF Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2013–N–1423] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Importer’s Entry Notice AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by April 14, 2014. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–7285, or emailed to oira_ submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0046. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 1350 Piccard Dr., PI50–400B, Rockville, MD 20850, PRAStaff@fda.hhs.gov. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. TKELLEY on DSK3SPTVN1PROD with NOTICES SUMMARY: Importer’s Entry Notice—(OMB Control Number 0910–0046)—Extension Section 801 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 381) charges the Secretary of Health and Human Services, through FDA, with the responsibility of assuring foreign-origin, FDA-regulated foods, drugs, cosmetics, medical devices, radiological health, and tobacco products offered for import into the United States meet the same requirements of the FD&C Act as do domestic products, and for preventing VerDate Mar<15>2010 17:33 Mar 12, 2014 Jkt 232001 products from entering the country if they are not in compliance. The discharge of this responsibility involves close coordination and cooperation between FDA headquarters and field inspectional personnel and the U.S. Customs Service (USCS), as the USCS is responsible for enforcing the revenue laws covering the very same products. This collection of information gathers data for FDA-regulated products being imported into the United States and is being used by FDA to review and prevent imported products from entering the United States if the products do not meet the same requirements of the FD&C Act as domestic products. Until October 1995, importers were required to file manual entries on OMBapproved forms that were accompanied by related documents. FDA did away with use of the paper forms effective October 1, 1995, to eliminate duplicity of information and to reduce the paperwork burden both on the import community and FDA. FDA then implemented an automated nationwide entry processing system, which enabled FDA to more efficiently obtain and process the information it requires to fulfill its regulatory responsibility. Most of the information FDA requires to carry out its regulatory responsibilities under section 801 is already provided electronically by filers to USCS. Because USCS relays this data to FDA using an electronic interface, the majority of data submitted by the entry filer need be completed only once. At each U.S. port of entry (seaport, landport, and airport) where foreignorigin, FDA-regulated products are offered for import, FDA is notified through USCS’s Automated Commercial System (ACS) by the importer (or his/ her agent) of the arrival of each entry. Following such notification, FDA reviews relevant data to ensure the imported product meets the standards as required for domestic products, decides on the admissibility of the imported product, and informs the importer and USCS of its decision. A single entry frequently contains multiple lines of different products. FDA may authorize products listed on specific lines to enter the United States unimpeded, while other products listed in the same entry may be held pending further FDA review/action. All entry data pass through a screening criteria program resident on a USCS computer. This screening program was developed and is PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 14255 maintained by FDA. This electronic screening criteria module makes the initial screening decision on every entry of foreign-origin, FDA-regulated product. Almost instantaneously after the entry is filed, the filer receives FDA’s admissibility decision for each entry, i.e., ‘‘MAY PROCEED’’ or ‘‘FDA REVIEW.’’ In addition to the information collected by USCS, FDA requires four additional pieces of information that were not available from USCS’s system in order to make an admissibility decision for each entry. These data elements include the FDA Product Code, FDA country of production, manufacturer/shipper, and ultimate consignee. OMB has previously approved the automated collection of these four data elements for tobacco products that filers could provide to FDA along with other entry-related information. Providing this information to FDA results in importers receiving an FDA admissibility decision more expeditiously, e.g., the quantity, value, and Affirmation(s) of Compliance with Qualifier(s). Since the inception of the interface with ACS, FDA’s electronic screening criteria program has been applied nationwide. This eliminates issues such as ‘‘port shopping’’ (attempts to intentionally slip products through one FDA port when refused by another, or filing entries at a port known to receive a high volume of entries). Every electronically submitted entry line of foreign-origin, FDA-regulated product undergoes automated screening and the screening criteria can be set to be as specific or as broad as applicable; changes are immediately effective. This capability is of tremendous value in protecting the public if there is a need to immediately halt specific product from entering the United States. If the data in this collection of information is not collected, FDA could not adequately meet its statutory responsibilities to regulate imported products, nor control potentially dangerous products from entering the U.S. marketplace. In the Federal Register of November 27, 2013 (78 FR 70951), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. FDA estimates the burden of this collection of information as follows: E:\FR\FM\13MRN1.SGM 13MRN1 14256 Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Number of respondents FDA imported products Number of responses per respondent Average burden per response Total annual responses Total hours Non-Tobacco ........................................................................ Tobacco ............................................................................... 3,406 330 1,089 68 3,709,134 22,440 2 0.14 2 0.14 519,279 3,142 Total .............................................................................. ........................ ........................ ........................ ........................ 522,421 1 There 2 (8 are no capital costs or operating and maintenance costs associated with this collection of information. minutes). The hourly burden for this information collection is based on FDA’s averaging of data obtained during a survey of nine representative filers nationwide and FDA’s experience. For purposes of comparison of hourly burden, the filers also were requested to provide the same information with regard to filing entries manually. FDA felt that the average time for completing either electronic or manual entries was very similar. Based on data collected by FDA’s survey of nine filers and its experience, the total annual burden to the import community to submit information electronically for 3,731,574 average annual responses was 522,421 hours. The previously OMB-approved hours per response (0.14 hours) are expected to remain the same. This burden includes the time FDA estimates it will take respondents to compile and provide documents to FDA for those entries where FDA cannot make an admissibility decision based on the electronic data alone. Based on the survey of nine filers and FDA’s past experience, FDA estimates that there will be no additional costs to provide import data electronically to FDA, as filers already have equipment and software in place to enable them to provide data to USCS via the automated system. Therefore, no additional software or hardware need be developed or purchased to enable filers to file the FDA data elements at the same time they file entries electronically with USCS. Dated: March 7, 2014. Leslie Kux, Assistant Commissioner for Policy. TKELLEY on DSK3SPTVN1PROD with NOTICES [FR Doc. 2014–05516 Filed 3–12–14; 8:45 am] BILLING CODE 4160–01–P VerDate Mar<15>2010 17:33 Mar 12, 2014 Jkt 232001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Proposed Collection; 60-Day Comment Request; Evaluation of National Institutes of Health International Bilateral Programs (FIC, NCI, NIAAA, NIAID, NICHD, NIDA, NINDS, NIMH, OAR) In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. To Submit Comments and For Further Information: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Julie Schneider, Program Director, Center for Global Health, National Cancer Institute, 9609 Medical Center Dr., RM 3W564, Rockville, MD 20850 or call non-tollfree number 240–276–5795 or Email SUMMARY: PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 your request, including your address to: schneidj@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing. DATES: Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Proposed Collection: Evaluation of National Institutes of Health International Bilateral Programs (FIC, NCI, NIAAA, NIAID, NICHD, NIDA, NIMH, NINDS, OAR), 0925–NEW, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: This submission is a request for OMB to approve the Evaluation of National Institutes of Health (NIH) International Bilateral Programs for three years. The bilateral awards are made through the Funding Opportunity Announcement mechanism and administrative supplements, meaning they are funded by set-aside funds that are separate from the general pool of research program grant funds used to support investigator initiated research at NIH. The bilateral programs to be evaluated are the U.S.-China Program for Biomedical Research Cooperation, U.S.—India Bilateral Collaborative Research Partnerships on the Prevention of HIV/AIDS and Co-morbidities, U.S.Russia Bilateral Collaborative Research Partnerships on the Prevention and Treatment of HIV/AIDS and Comorbidities, and U.S.-South Africa Program for Collaborative Biomedical Research. These programs are funded and administered by various combinations of the following institutes: Fogarty International Center (FIC), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute for Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke E:\FR\FM\13MRN1.SGM 13MRN1

Agencies

[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Pages 14255-14256]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05516]



[[Page 14255]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-1423]


Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; Importer's Entry 
Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that a 
proposed collection of information has been submitted to the Office of 
Management and Budget (OMB) for review and clearance under the 
Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by April 
14, 2014.

ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be faxed to the Office 
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, 
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All 
comments should be identified with the OMB control number 0910-0046. 
Also include the FDA docket number found in brackets in the heading of 
this document.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, 
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, 
MD 20850, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Importer's Entry Notice--(OMB Control Number 0910-0046)--Extension

    Section 801 of the Federal Food, Drug, and Cosmetic Act (the FD&C 
Act) (21 U.S.C. 381) charges the Secretary of Health and Human 
Services, through FDA, with the responsibility of assuring foreign-
origin, FDA-regulated foods, drugs, cosmetics, medical devices, 
radiological health, and tobacco products offered for import into the 
United States meet the same requirements of the FD&C Act as do domestic 
products, and for preventing products from entering the country if they 
are not in compliance. The discharge of this responsibility involves 
close coordination and cooperation between FDA headquarters and field 
inspectional personnel and the U.S. Customs Service (USCS), as the USCS 
is responsible for enforcing the revenue laws covering the very same 
products.
    This collection of information gathers data for FDA-regulated 
products being imported into the United States and is being used by FDA 
to review and prevent imported products from entering the United States 
if the products do not meet the same requirements of the FD&C Act as 
domestic products.
    Until October 1995, importers were required to file manual entries 
on OMB-approved forms that were accompanied by related documents. FDA 
did away with use of the paper forms effective October 1, 1995, to 
eliminate duplicity of information and to reduce the paperwork burden 
both on the import community and FDA. FDA then implemented an automated 
nationwide entry processing system, which enabled FDA to more 
efficiently obtain and process the information it requires to fulfill 
its regulatory responsibility.
    Most of the information FDA requires to carry out its regulatory 
responsibilities under section 801 is already provided electronically 
by filers to USCS. Because USCS relays this data to FDA using an 
electronic interface, the majority of data submitted by the entry filer 
need be completed only once.
    At each U.S. port of entry (seaport, landport, and airport) where 
foreign-origin, FDA-regulated products are offered for import, FDA is 
notified through USCS's Automated Commercial System (ACS) by the 
importer (or his/her agent) of the arrival of each entry. Following 
such notification, FDA reviews relevant data to ensure the imported 
product meets the standards as required for domestic products, decides 
on the admissibility of the imported product, and informs the importer 
and USCS of its decision. A single entry frequently contains multiple 
lines of different products. FDA may authorize products listed on 
specific lines to enter the United States unimpeded, while other 
products listed in the same entry may be held pending further FDA 
review/action.
    All entry data pass through a screening criteria program resident 
on a USCS computer. This screening program was developed and is 
maintained by FDA. This electronic screening criteria module makes the 
initial screening decision on every entry of foreign-origin, FDA-
regulated product. Almost instantaneously after the entry is filed, the 
filer receives FDA's admissibility decision for each entry, i.e., ``MAY 
PROCEED'' or ``FDA REVIEW.''
    In addition to the information collected by USCS, FDA requires four 
additional pieces of information that were not available from USCS's 
system in order to make an admissibility decision for each entry. These 
data elements include the FDA Product Code, FDA country of production, 
manufacturer/shipper, and ultimate consignee. OMB has previously 
approved the automated collection of these four data elements for 
tobacco products that filers could provide to FDA along with other 
entry-related information. Providing this information to FDA results in 
importers receiving an FDA admissibility decision more expeditiously, 
e.g., the quantity, value, and Affirmation(s) of Compliance with 
Qualifier(s).
    Since the inception of the interface with ACS, FDA's electronic 
screening criteria program has been applied nationwide. This eliminates 
issues such as ``port shopping'' (attempts to intentionally slip 
products through one FDA port when refused by another, or filing 
entries at a port known to receive a high volume of entries). Every 
electronically submitted entry line of foreign-origin, FDA-regulated 
product undergoes automated screening and the screening criteria can be 
set to be as specific or as broad as applicable; changes are 
immediately effective. This capability is of tremendous value in 
protecting the public if there is a need to immediately halt specific 
product from entering the United States.
    If the data in this collection of information is not collected, FDA 
could not adequately meet its statutory responsibilities to regulate 
imported products, nor control potentially dangerous products from 
entering the U.S. marketplace.
    In the Federal Register of November 27, 2013 (78 FR 70951), FDA 
published a 60-day notice requesting public comment on the proposed 
collection of information. No comments were received.
    FDA estimates the burden of this collection of information as 
follows:

[[Page 14256]]



                                 Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                     Number of                        Average
      FDA imported products          Number of     responses per   Total annual     burden per     Total  hours
                                    respondents     respondent       responses       response
----------------------------------------------------------------------------------------------------------------
Non-Tobacco.....................           3,406           1,089       3,709,134        \2\ 0.14         519,279
Tobacco.........................             330              68          22,440        \2\ 0.14           3,142
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............         522,421
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.
\2\ (8 minutes).

    The hourly burden for this information collection is based on FDA's 
averaging of data obtained during a survey of nine representative 
filers nationwide and FDA's experience. For purposes of comparison of 
hourly burden, the filers also were requested to provide the same 
information with regard to filing entries manually. FDA felt that the 
average time for completing either electronic or manual entries was 
very similar.
    Based on data collected by FDA's survey of nine filers and its 
experience, the total annual burden to the import community to submit 
information electronically for 3,731,574 average annual responses was 
522,421 hours. The previously OMB-approved hours per response (0.14 
hours) are expected to remain the same.
    This burden includes the time FDA estimates it will take 
respondents to compile and provide documents to FDA for those entries 
where FDA cannot make an admissibility decision based on the electronic 
data alone. Based on the survey of nine filers and FDA's past 
experience, FDA estimates that there will be no additional costs to 
provide import data electronically to FDA, as filers already have 
equipment and software in place to enable them to provide data to USCS 
via the automated system. Therefore, no additional software or hardware 
need be developed or purchased to enable filers to file the FDA data 
elements at the same time they file entries electronically with USCS.

    Dated: March 7, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-05516 Filed 3-12-14; 8:45 am]
BILLING CODE 4160-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.